Placental ferritin is a tumour associated antigen present in the serum of patients with active Hodgkin's and non-Hodgkin's
remission of the disease. There is no correlation between placental and total blood ferritin values. Because of the strong association between coeliac disease and lymphoma, 19 children with active and 25 with inactive coeliac disease were screened for the presence of placental ferritin. Thirty two children with other intestinal disorders served as controls. Placental ferritin was identified by using a monoclonal antibody in an ELISA procedure. The mean (SEM) placental ferritin value in the control serum was 12*6 (2.4) while the values in serum of patients with active and inactive coeliac disease were 117 (22.8) and (10-2) U/ml respectively. Patients with active coeliac disease differed significantly from both control subjects (p=00004) and those with inactive disease (p=003). Peripheral blood lymphocytes contained no placental ferritin. It was present, however, in lamina propria lymphocytes of intestinal biopsy specimens from active coeliacs. Placental ferritin was also found in some of the better differentiated malignant cells in two patients with adult onset enteropathy associated lymphoma. Placental ferritin is known to have an immunosuppressive effect, and this may be one of the necessary steps in the development of malignancy associated with coeliac disease. Gluten free diet, by reversing this state, may have a role in the prevention of lymphoma. show a specific placental ferritin isoform.7 It was found that placental ferritin was not detected in most healthy adult blood donors but it was raised in the sera of patients with lymphoproliferative disorders.7
In a preliminary communication, 8 we reported that serum placental ferritin values are increased in active coeliac disease, and decrease after initiation of a gluten free diet. The purpose of this study was to expand the number of patients studied, to identify the cellular origin of placental ferritin, and to formulate a hypothesis on its role in the development of lymphoma in coeliac disease patients.
Patients and methods

PATIENTS
Sera from 19 children with active coeliac disease and 25 children with the disease in remission were screened. The diagnosis of coeliac disease was made according to the European Society for Paediatric Gastroenterology and Nutrition criteria.9 Thirty two children with irritable bowel, abdominal pain, or constipation served as control subjects. Sera from children with active disease were collected either at the time of initial diagnosis or during a period of gluten challenge, when they were shown to have subtotal villous atrophy. Sera from children with inactive coeliac disease were collected after at least one year on a gluten free diet. Gluten free diet was shown to cause morphological recovery in all patients, and in eight children the biopsy specimens showing recovery were taken within three months of the placental ferritin determination. All tests were done on blood samples taken during routine clinical evaluation of the patients or from our sera bank. The mean (SEM) age of the control subjects was 9 (0-9) years (median 8, range [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] years); that of the children with active disease was 9 9 (0 8) years (median 9 5, range 5-13 years); and the age of those with inactive coeliac disease was 9 (0 8) years (median 8, range 2-5-19 years). There was no significant difference between the three groups. ENZYME LINKED IMMUNOSORBENT ASSAiY (ELISA) PROCEDURE FOR PLACENTAL FERRITIN Serum placental ferritin concentrations were determined by a previously described ELISA method.7 10 The assay uses two monoclonal antibodies (CM-G-8) and CM-H-9) developed by one of us (CM). Monoclonal antibody CM-G-8 binds to all isoferritins, whereas CM-H-9 binds to placental ferritin only. In brief, CM-G-8 was coupled to the solid phase, and test sera were added to the wells. After incubation and washing, alkaline phosphatase conjugated CM-H-9 was added to each well. Colour was developed by the addition of p-nitrophenylphosphate substrate, and read in an ELISA reader at 405 nm. The amount of placental ferritin that bound 250 pg of alkaline phosphatase conjugated CM-H-9 was arbitrarily considered to be 10 U of placental ferritin, and the results were expressed as U/ml. bated with 25 p1 of diluted monoclonal antibody CM-H-9 overnight at 4°C. After three washes in BSA-PBS, the cells were incubated with 25 p1 fluorescein conjugated rabbit anti-mouse immunoglobulin (Dakopatts, Denmark) for 30 minutes at room temperature. After three washes and centrifugation, the cell pellets were suspended in 20 p1 of BSA-PBS and examined with a fluorescence microscope, with an excitation wave length of 288 nm. ISOLATION hydrogen peroxide in PBS. The slides were then washed and counterstained with haematoxylin. Control sections were incubated with normal rabbit serum instead of CM-H-9.
STATISTICAL ANALYSIS
This was performed using the Mann-Whitney U test (non-parametric).
Results
The results of serum placental ferritin concentrations are shown in Figure 1 . The mean (SEM) control value was 12-6 (2-4) while those of the patients with active and inactive coeliac disease were 117 (22 8) and 43'8 (10-2) U/ml, respectively. Children with active coeliac disease differed significantly from both control subjects (p<0 00001) and those with inactive disease (p<0006). Controls and children with inactive disease also differed significantly (p<003). Only eight of the 25 children with inactive coeliac disease had a serum placental ferritin value above the upper limit of normal, which is 40 U/ml, while concentrations were increased in most of the children with active coeliac disease (13 of 19 children).
Four patients with active coeliac disease were studied longitudinally. Placental ferritin values decreased after eight to 18 months on a gluten free diet (data not shown). (Original magnification x400.)
Staining peripheral blood lymphocytes failed to show placental ferritin, either in the cytoplasm or on the cell membranes.
Immune staining of intestinal biopsy specimens from children with active coeliac disease showed that approximately 40-50% of the lamina propria lymphocytes were positive for placental ferritin (Fig 2) . Very few intraepithelial lymphocytes were found to contain placental ferritin, and epithelial intestinal cells were always negative for this. Nor did biopsy specimens from control subjects, children with inactive coeliac disease, or Crohn's disease contain placental ferritin bearing lymphocytes.
About 20% of the smaller, better differentiated malignant cells in biopsy specimens of enteropathy associated lymphoma from two adult patients stained positively for placental ferritin (Fig 3) . Figure 4 : Hypothesis on the possible role ofplacentalferritin (PLF) in the development oflymphoma in coeliac disease. An unknown trigger induces PLF production in some intestinal lymphocytes. Gluten enhances, and gluten free diet inhibits, continuing proliferation ofthese lymphocytes. Other triggers may cause malignant transformation ofPLF producing lamina propria lymphocytes, and production ofPLF receptor bearing CD8 cells. In the presence ofPLF, immunosuppression is produced, which may allow expansion ofthe malignant cell population and production oflymphoma.
ferritin originates in lamina propria lymphocytes.
It is now generally accepted that there are two distinct populations of lymphoid cells residing in the gut mucosa -those in the lamina propria and the intraepithelial lymphocytes. The former are mostly of the helper phenotype, while the latter are predominantly cytotoxic-suppressor.'7 We were not able to characterise directly the intestinal placental ferritin positive cells in our patients, but the fact that most are in the lamina propria and not intraepithelial lymphocytes, suggests that they are of the helper (CD4) phenotype. This is consistent with the findings in early HIV infection, where placental ferritin is thought to originate in CD4 lymphocytes. 16 In coeliac disease, the secretion of placental ferritin may be activated by some trigger (such as adenovirus, which contains a protein similar to an amino acid sequence of a gliadin), '8 and maintained by gluten. Continuous proliferation of the intestinal placental ferritin secreting lymphocytes may increase the risk of malignant transformation.
Immunosuppression, caused by placental ferritin in the presence of placental ferritin receptor bearing suppressor (CD8) cells'9 or by a gliadin,20 may facilitate the development of lymphoma from transformed, placental ferritin producing, intestinal lymphocytes.
If the above speculation regarding the development of lymphoma, summarised in Figure 4 , is true, then the appearance of placental ferritin may be one of the steps required for the development of malignancy. A gluten free diet, by inhibiting its production, may prevent lymphoma development. The presence of placental ferritin positive cells in the slides from the patients with adult onset enteropathy associated T cell lymphoma lends further support to our hypothesis. Only smaller, well differentiated malignant cells were found to be placental ferritin positive. This is consistent with previous observations in non-Hodgkin's lymphoma, where the highest placental ferritin values were found in sera from patients with low grade lymphoma, which represents the most differentiated tumour cells.7
It is not known if strict adherence to gluten free diet in childhood will reduce the risk of developing lymphoma in patients with coeliac disease. Nevertheless, preliminary results suggest that gluten free diet may indeed have a role in the prevention of malignancy. [21] [22] [23] Patients on a gluten free diet in whom placental ferritin does not decrease may prove to be in a higher risk category for the development of malignancy, when other factors are controlled. Monitoring placental ferritin values in coeliac disease patients may help identify those at high risk and thereby enable early diagnosis.
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